IBRUTINIB CAPSULE 140MG

Ibrutinib Capsule 140mg is an advanced targeted anticancer therapy used in the treatment of serious blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, and marginal zone lymphoma. Classified as a Bruton’s tyrosine kinase (BTK) inhibitor, this precision medicine is designed to disrupt cancer cell survival pathways.

Ibrutinib works by blocking BTK signaling, a critical pathway that supports the growth and spread of malignant B-cells. By interfering with these signals, the medicine helps slow disease progression, reduce cancer cell activity, and promote long-term disease control in patients with hematological malignancies.

When taken strictly under an oncologist’s supervision, Ibrutinib 140 mg Capsules support sustained treatment outcomes and improved quality of life for eligible patients. Its oral capsule form offers convenient daily dosing while delivering highly targeted, clinically proven cancer therapy as part of a comprehensive treatment plan.

Product Features

• BTK (Bruton’s tyrosine kinase) inhibitor
• Used in multiple blood cancers, including CLL and MCL
• Oral targeted therapy capsule
• Helps inhibit cancer cell growth and survival pathways
• Suitable for long-term treatment as prescribed
• Prescription-only oncology medication

How It Helps

• Blocks BTK signaling to slow the growth of cancerous B-cells
• Helps control disease progression in blood cancers like CLL and MCL
• Reduces survival signals that allow cancer cells to multiply
• Supports long-term targeted management of hematological malignancies